Protagonist Therapeutics PTGX
NASDAQ PTGX
$141.36 +0.39 (+0.28%)
As of: Sep 30, 2026 · 2:50 PM EDT

Protagonist Therapeutics (PTGX) EV to EBIT (2024 - 2026)

Updated

Protagonist Therapeutics' EV to EBIT came in at 122.47 for Q2 2026, up 2.6% from 119.38 a year earlier.

Analysis

Protagonist Therapeutics (PTGX) EV to EBIT (2024 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Protagonist Therapeutics reported EV to EBIT of 93.48, up 60.1% year-over-year; for FY2024, it was 7.66.

  • The five-year range for quarterly EV to EBIT is 7.66 (Q4 2024) to 187.93 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Protagonist Therapeutics 9.12 Bn 9.12 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 122.47
Sep 30, 2025 187.93
Jun 30, 2025 119.38
Mar 31, 2025 88.91
Dec 31, 2024 7.66
Sep 30, 2024 14.82
Jun 30, 2024 9.67
Mar 31, 2024 9.23
API Access

Protagonist Therapeutics EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=PTGX&period=max&api_key=YOUR_API_KEY